Baxter/Halozyme's HyQvia wins EU nod for immunodeficiencies

05/23/2013 | PharmaTimes (U.K.)

Baxter International and Halozyme Therapeutics obtained approval from the European Commission to market HyQvia as a replacement treatment for adults with primary and secondary immunodeficiency disorders. The treatment, a combination of human normal immunoglobulin and recombinant human hyaluronidase, is intended to be taken once every three to four weeks.

View Full Article in:

PharmaTimes (U.K.)

Published in Briefs:

SmartBrief Job Listings for Health Care

Job Title Company Location
Director, Senior Legal Counsel
Alcon
Fort Worth, TX
Senior Scientist - Cell Engineering Group
Pfizer
San Francisco, CA
Associate Director, Compliance Business Partner I
Boehringer Ingelheim
Ridgefield, CT
Attorney
U.S. DEPARTMENT OF HEALTH & HUMAN SERVICES Food and Drug Administration Office of the Chief Counsel
Silver Spring, MD, MD
Counsel – Regulatory Affairs
RAI Services Company
Winston Salem, NC